These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30400962)

  • 1. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer.
    Ma SJ; Prezzano KM; Hermann GM; Singh AK
    Radiat Oncol; 2018 Nov; 13(1):214. PubMed ID: 30400962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
    Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
    Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
    Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
    Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of survival with stereotactic body radiation therapy following induction chemotherapy for unresected locally advanced pancreatic cancer.
    Ma SJ; Serra LM; Bartl AJ; Han HR; Fekrmandi F; Iovoli AJ; Prezzano KM; Hermann GM; Yu H; Singh AK
    J Radiother Pract; 2022 Sep; 21(3):403-410. PubMed ID: 36016862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
    Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
    Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
    Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
    Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
    Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
    Golden DW; Novak CJ; Minsky BD; Liauw SL
    Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
    Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C
    BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.
    Brower JV; Amini A; Chen S; Hullett CR; Kimple RJ; Wojcieszynski AP; Bassetti M; Witek ME; Yu M; Harari PM; Baschnagel AM
    Ann Oncol; 2016 Oct; 27(10):1887-94. PubMed ID: 27502703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.
    Torgeson A; Lloyd S; Boothe D; Tao R; Whisenant J; Garrido-Laguna I; Cannon GM
    Cancer; 2017 Oct; 123(19):3816-3824. PubMed ID: 28621885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.
    Ma SJ; Hermann GM; Prezzano KM; Serra LM; Iovoli AJ; Singh AK
    Cancer Med; 2019 Mar; 8(3):939-952. PubMed ID: 30652417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
    Brower JV; Chen S; Bassetti MF; Yu M; Harari PM; Ritter MA; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):985-993. PubMed ID: 27869098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.
    Krishnan S; Chadha AS; Suh Y; Chen HC; Rao A; Das P; Minsky BD; Mahmood U; Delclos ME; Sawakuchi GO; Beddar S; Katz MH; Fleming JB; Javle MM; Varadhachary GR; Wolff RA; Crane CH
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):755-65. PubMed ID: 26972648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer.
    Shah NK; Qureshi MM; Dyer MA; Patel SA; Kim K; Everett PC; Grillone GA; Jalisi SM; Truong MT
    Laryngoscope; 2019 Oct; 129(10):2313-2320. PubMed ID: 30628077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
    Hsu CC; Herman JM; Corsini MM; Winter JM; Callister MD; Haddock MG; Cameron JL; Pawlik TM; Schulick RD; Wolfgang CL; Laheru DA; Farnell MB; Swartz MJ; Gunderson LL; Miller RC
    Ann Surg Oncol; 2010 Apr; 17(4):981-90. PubMed ID: 20087786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
    Leone F; Gatti M; Massucco P; Colombi F; Sperti E; Campanella D; Regge D; Gabriele P; Capussotti L; Aglietta M
    Cancer; 2013 Jan; 119(2):277-84. PubMed ID: 22778019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer.
    Goto Y; Nakamura A; Ashida R; Sakanaka K; Itasaka S; Shibuya K; Matsumoto S; Kanai M; Isoda H; Masui T; Kodama Y; Takaori K; Hiraoka M; Mizowaki T
    Radiat Oncol; 2018 Jun; 13(1):118. PubMed ID: 29940984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer.
    Kelly P; Das P; Pinnix CC; Beddar S; Briere T; Pham M; Krishnan S; Delclos ME; Crane CH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e143-9. PubMed ID: 23200173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
    Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
    Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.